In this video and audio edition of Ethics Talk, journal editor in chief, Dr Audiey Kao, talks with Dr Olivia Kates about appropriate use of antibiotics during the COVID-19 pandemic.

Click here to read the transcript.

Olivia Kates, MD is a third-year fellow in infectious diseases at the University of Washington in Seattle. 

Video

Recorded on May 17, 2021

May 2021

• Decision making
• Infectious diseases
• Infectious diseases/Epidemics

Infectious Disease Medical Knowledge Patient Care

Audio

 

Conflict of Interest Disclosure
Interviewee had no conflicts of interest to disclose.

Viewpoints expressed are those of interview participants and do not necessarily reflect the views and policies of the AMA.

Jun 2006

Unnecessary Antibiotics

Jonathan A. Finkelstein, MD, MPH

Oct 2017

Should Physicians Consider the Environmental Effects of Prescribing Antibiotics?

Jeremy Balch, Julia H. Schoen, MS, and Payal K. Patel, MD, MPH

Header Image Issue Ending the HIV Epidemic Off

In this video and audio edition of Ethics Talk, journal editor in chief, Dr Audiey Kao, talks with Dr Caleb Alexander about the US Food and Drug Administration's controversial decision to approve aducanumab for the treatment of Alzheimer's Disease.

Click here to read the transcript.

G. Caleb Alexander, MD, MS is professor of epidemiology and medicine at Johns Hopkins Bloomberg School of Public Health.

Video

Recorded on June 22, 2021

 

Jun 2021

• Clinical research
• Public health/Public policy intervention
• Access to care/Cost barriers
• High value care/Cost of care

Neurology Patient Care

Audio

 

Conflict of Interest Disclosure

Dr Alexander is past chair and current member of FDA's Peripheral and Central Nervous System Drugs Advisory Committee. He is a co-founding principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation. He was also a member of OptumRx's National Pharmacy and Therapeutics Committee.

Viewpoints expressed are those of interview participants and do not necessarily reflect the views and policies of the AMA.

Aug 2013

The Terminally Ill, Access to Investigational Drugs, and FDA Rules

Valarie Blake, JD, MA

Sep 2015

After Equipoise: Continuing Research to Gain FDA Approval

Allison Kerianne Crockett, MD

Jun 2012

Antidepressants and the FDA’s Black-Box Warning: Determining a Rational Public Policy in the Absence of Sufficient Evidence

Dien Ho, PhD

Header Image Issue Visibility and Measurability in Health Care Off